Synexis LLC, pioneer in microbial reduction and sole developer of hydrogen peroxide gas and Dry Hydrogen Peroxide (DHP™) technology for occupied spaces, announced positive new data from a retrospective analysis evaluating the use of DHP™ Technology in a clinical setting were published in the current issue of the American Journal of Infection Control (AJIC). The retrospective analysis assessed the efficacy of DHP™ Technology, in addition to standard manual cleaning, in reducing hospital-acquired infections (HAIs) in the intensive care unit (ICU) of a pediatric oncology hospital. As an adjunct technology for environmental cleaning, DHP™ contributed to the reduction in HAIs in this clinical setting.
Also Read: DocGo Provides Advanced Life Support Vehicles to Assist Upstate New York Hospitals
“Standard cleaning and disinfecting protocols may not be sufficient for immunocompromised patients who are particularly susceptible to HAIs,” said Dr. Mario Melgar, Medical Director for Infection and Control. Synexis develops cutting-edge BioDefense systems designed to transform the air to make the air and surfaces cleaner.
The study was conducted between January 2019 and November 2020 at the pediatric ICU (PICU) at Unidad Nacional de Oncología Pediátrica (UNOP), the National Referral Center for Children with Cancer and a global partner of a leading pediatric cancer institution in the U.S. UNOP is a 65-bed pediatric oncology hospital located in Guatemala City, Guatemala. Though they follow all CDC guidelines and protocols for preventing HAIs, DHP™ Technology was added to standard environmental cleaning and disinfection in the PICU to determine its effect on HAI rates.
“This study demonstrates the value of DHP™ Technology. I am thrilled to see the significant decrease of C. diff incidence in our PICU,” said Dr. Alicia Chang, Department of Infectious Diseases. “We continue to follow the CDC’s recommended prevention and control strategies, and the addition of DHP™ to our environmental cleaning process helped optimize our outcomes.”
Between 2019 and 2020, the addition of DHP™ to standard cleaning resulted in a 44.3% reduction in HAI incidence (incidence rate difference, IRD = -21.20, p=0.0277) in the PICU, including a 76.4% reduction in Clostridioides-associated gastroenteritis (IRD=-8.23, p=0.0482), compared to the period before DHP™ installation. Additionally, only one case of hospital-acquired COVID-19-associated non-pneumonia respiratory infection occurred in the PICU where DHP™ was installed compared to a control area without DHP™ which experienced an increase in hospital-acquired non-pneumonia respiratory infections (IRD=2.52; p=0.028).